focus -WSS

focus

author：fashion 2025-09-05 13:47:51 - browse：22128

Blood corpuscles in clot — Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. David Gregory & Debbie Marshall/Wellcome Images

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.

LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.

Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Former medical device CEO who sold dummy, plastic parts convicted of fraud

focus

WSS

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

IVF, abortion rights issues kick off Biden’s State of the Union

Violet CEO on training clinicians to promote more inclusive care

IVF, abortion rights issues kick off Biden’s State of the Union

Medicare Advantage beneficiaries sue Humana over algorithm use

HCA sued by state AG for quality issues at Mission Health

knowledge

focus

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

NEJM study link tiny plastics in blood vessels to heart problems

United colonoscopy coverage change 'may cost lives,' doctors say

Why health records don't always know when patients are dead

Alkermes shareholders re

Prime Medicine, Myeloid Therapeutics clash over genome

What does generative AI mean for health care? We asked experts

Can sheer will power keep patients alive in their dying hours?

As demand for Covid shots wanes, Moderna seeks its next success

Christmas in the PICU brings some surprising joy

knowledge

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

CRISPR gene editing developments we’re watching in 2024

Three trends to watch in biotech in 2024

With psoriasis trial ahead, Alumis raises $259 million

Violet CEO on training clinicians to promote more inclusive care

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

focus

focus

leisure time

Wikipedia